NJ Bio, Inc., a premier contract research and clinical manufacturing service provider in Princeton, New Jersey has announced the asset purchase and full integration of the research services of L2P Research Labs® (“Lab to Pharmacy”), further expanding its service portfolio, and bridging the translational research gap. L2P Research Labs® was well-recognized for its integrated pre-clinical R&D support, particularly in oncology research and for services supporting IND applications. With the integration of these services into NJ Bio’s offerings, L2P Research Labs®, has ceased independent operations and its portfolio of preclinical and translational research services will now be offered exclusively under NJ Bio.
Read the full article: NJ Bio Bridges the Translation Research Gap with the Asset Purchase and Integration of L2P® Services //
Source: https://www.businesswire.com/news/home/20251106703527/en/NJ-Bio-Bridges-the-Translation-Research-Gap-with-the-Asset-Purchase-and-Integration-of-L2P-Services